These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
116 related articles for article (PubMed ID: 33353722)
21. Molecular Imaging and Updated Diagnostic Criteria in Lewy Body Dementias. Bohnen NI; Müller MLTM; Frey KA Curr Neurol Neurosci Rep; 2017 Aug; 17(10):73. PubMed ID: 28808912 [TBL] [Abstract][Full Text] [Related]
22. Parkinson's disease dementia: convergence of α-synuclein, tau and amyloid-β pathologies. Irwin DJ; Lee VM; Trojanowski JQ Nat Rev Neurosci; 2013 Sep; 14(9):626-36. PubMed ID: 23900411 [TBL] [Abstract][Full Text] [Related]
23. Concurrence of TDP-43, tau and alpha-synuclein pathology in brains of Alzheimer's disease and dementia with Lewy bodies. Higashi S; Iseki E; Yamamoto R; Minegishi M; Hino H; Fujisawa K; Togo T; Katsuse O; Uchikado H; Furukawa Y; Kosaka K; Arai H Brain Res; 2007 Dec; 1184():284-94. PubMed ID: 17963732 [TBL] [Abstract][Full Text] [Related]
24. Value of neuropsychological testing, imaging, and CSF biomarkers for the differential diagnosis and prognosis of clinically ambiguous dementia. Boutoleau-Bretonnière C; Lebouvier T; Delaroche O; Lamy E; Evrard C; Charriau T; Bretonnière C; Damier P; Derkinderen P; Vercelletto M J Alzheimers Dis; 2012; 28(2):323-36. PubMed ID: 22008265 [TBL] [Abstract][Full Text] [Related]
25. Cross-validation of biomarkers for the early differential diagnosis and prognosis of dementia in a clinical setting. Perani D; Cerami C; Caminiti SP; Santangelo R; Coppi E; Ferrari L; Pinto P; Passerini G; Falini A; Iannaccone S; Cappa SF; Comi G; Gianolli L; Magnani G Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):499-508. PubMed ID: 26341365 [TBL] [Abstract][Full Text] [Related]
26. Molecular imaging of dementia. Mori T; Maeda J; Shimada H; Higuchi M; Shinotoh H; Ueno S; Suhara T Psychogeriatrics; 2012 Jun; 12(2):106-14. PubMed ID: 22712644 [TBL] [Abstract][Full Text] [Related]
27. Cerebrospinal fluid Tau/α-synuclein ratio in Parkinson's disease and degenerative dementias. Parnetti L; Chiasserini D; Bellomo G; Giannandrea D; De Carlo C; Qureshi MM; Ardah MT; Varghese S; Bonanni L; Borroni B; Tambasco N; Eusebi P; Rossi A; Onofrj M; Padovani A; Calabresi P; El-Agnaf O Mov Disord; 2011 Jul; 26(8):1428-35. PubMed ID: 21469206 [TBL] [Abstract][Full Text] [Related]
28. Autopsy-diagnosed neurodegenerative dementia cases support the use of cerebrospinal fluid protein biomarkers in the diagnostic work-up. Bruzova M; Rusina R; Stejskalova Z; Matej R Sci Rep; 2021 May; 11(1):10837. PubMed ID: 34035398 [TBL] [Abstract][Full Text] [Related]
29. Protein coding of neurodegenerative dementias: the neuropathological basis of biomarker diagnostics. Kovacs GG; Botond G; Budka H Acta Neuropathol; 2010 Apr; 119(4):389-408. PubMed ID: 20198481 [TBL] [Abstract][Full Text] [Related]
30. The future of Cochrane Neonatal. Soll RF; Ovelman C; McGuire W Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834 [TBL] [Abstract][Full Text] [Related]
31. Associations Between APOE Variants, Tau and α-Synuclein. Rodriguez-Vieitez E; Nielsen HM Adv Exp Med Biol; 2019; 1184():177-186. PubMed ID: 32096038 [TBL] [Abstract][Full Text] [Related]
32. Large inter- and intra-case variability of first generation tau PET ligand binding in neurodegenerative dementias. Wren MC; Lashley T; Årstad E; Sander K Acta Neuropathol Commun; 2018 May; 6(1):34. PubMed ID: 29716656 [TBL] [Abstract][Full Text] [Related]
34. Clinic-Based Validation of Cerebrospinal Fluid Biomarkers with Florbetapir PET for Diagnosis of Dementia. Álvarez I; Aguilar M; González JM; Ysamat M; Lorenzo-Bosquet C; Alonso A; Tartari JP; Romero S; Diez-Fairen M; Carcel M; Pujalte F; Pastor P J Alzheimers Dis; 2018; 61(1):135-143. PubMed ID: 29154286 [TBL] [Abstract][Full Text] [Related]
35. The role of CSF biomarkers in the diagnostic work-up of mixed vascular-degenerative dementia. Engelborghs S; Le Bastard N J Neurol Sci; 2012 Nov; 322(1-2):197-9. PubMed ID: 22947896 [TBL] [Abstract][Full Text] [Related]